Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (341-350 of 578) with videos related to

Pageof 58
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trialEric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, et al.
International Journal of Cancer|April 27, 2024
Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortiumEva Obermayr, Thomas Mohr, Eva Schuster, et al.
International Journal of Cancer|May 6, 2024
Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortiumGesa Fromhage, Eva Obermayr, Natalia Bednarz-Knoll, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2023
Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994Gemma G Kenter, Stefano Greggi, Ignace Vergote, et al.
Cancers|September 9, 2020
Definition and Independent Validation of a Proteomic-Classifier in Ovarian CancerSabine Kasimir-Bauer, Joanna Roder, Eva Obermayr, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 27, 2010
Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancerIgnace Vergote, Neil J Finkler, James B Hall, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 19, 2021
European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinomaNicole Concin, François Planchamp, Nadeem R Abu-Rustum, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 1, 2015
The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD studyMani Nassir, Jun Guan, Hrvoje Luketina, et al.
BMC Cancer|September 19, 2013
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortiumAnna Bachmayr-Heyda, Stefanie Aust, Georg Heinze, et al.
Gynecologic Oncology|July 15, 2014
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancerIgnace Vergote, Russell J Schilder, Charles H Pippitt, et al.
Pageof 58

Showing results (341-350 of 578) with videos related to

Sort By:
Pageof 58
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trialEric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, et al.
International Journal of Cancer|April 27, 2024
Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortiumEva Obermayr, Thomas Mohr, Eva Schuster, et al.
International Journal of Cancer|May 6, 2024
Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortiumGesa Fromhage, Eva Obermayr, Natalia Bednarz-Knoll, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2023
Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994Gemma G Kenter, Stefano Greggi, Ignace Vergote, et al.
Cancers|September 9, 2020
Definition and Independent Validation of a Proteomic-Classifier in Ovarian CancerSabine Kasimir-Bauer, Joanna Roder, Eva Obermayr, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 27, 2010
Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancerIgnace Vergote, Neil J Finkler, James B Hall, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 19, 2021
European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinomaNicole Concin, François Planchamp, Nadeem R Abu-Rustum, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 1, 2015
The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD studyMani Nassir, Jun Guan, Hrvoje Luketina, et al.
BMC Cancer|September 19, 2013
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortiumAnna Bachmayr-Heyda, Stefanie Aust, Georg Heinze, et al.
Gynecologic Oncology|July 15, 2014
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancerIgnace Vergote, Russell J Schilder, Charles H Pippitt, et al.
Pageof 58